You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 9,441,046

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,441,046

Title:	Methods for increasing forced expiratory volume in asthmatics using benralizumab
Abstract:	Provided herein is are methods of increasing forced expiratory volume in one second (FEV.sub.1) in an asthma patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
Inventor(s):	Ward; Christine (Gaithersburg, MD), Roskos; Lorin (Gaithersburg, MD), Wang; Bing (Gaithersburg, MD), Raible; Donald (Berwyn, PA)
Assignee:	ASTRAZENECA AB (Sodertalje, SE)
Application Number:	14/454,138
Patent Claims:	1. A method of treating asthma by increasing forced expiratory volume in one second (FEV1) in an adult asthma patient, comprising administering subcutaneously to the adult patient a dose of 30 mg once every four weeks for twelve weeks and then once every eight weeks of benralizumab or an antigen-binding fragment thereof, wherein the administration increases the patient's FEV1. 2. The method of claim 1, wherein the administration increases the patient's FEV1 within 4 weeks of the first administration. 3. The method of claim 1, wherein the asthma is eosinophilic asthma. 4. The method of claim 1, wherein the patient has a blood eosinophil count of at least 300 cells/.mu.l. 5. The method of claim 1, wherein, the patient has a forced expiratory volume in one second (FEV1) of at least 75% predicted value prior to the administration. 6. The method of claim 1, wherein the FEV1 is increased by at least 0.1 L. 7. The method of claim 1, wherein the patient uses high-dose inhaled corticosteroids (ICS). 8. The method of claim 1, wherein the patient uses long-acting (32 agonists (LABA). 9. The method of claim 1, wherein the patient has a history of exacerbations. 10. The method of claim 1, wherein the benralizumab or antigen-binding fragment thereof is administered in addition to corticosteroid therapy.

Details for Patent 9,441,046

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Astrazeneca Ab	FASENRA	benralizumab	Injection	761070	11/14/2017	⤷ Try a Trial	2033-08-12
Astrazeneca Ab	FASENRA	benralizumab	Injection	761070	10/03/2019	⤷ Try a Trial	2033-08-12
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.